Heparanase link between vasculogenesis and angiogenesis as well as a predictive factor of a shorter survival rate

• Published in: Journal of physiology and pharmacology : an official journal of the Polish Physiological Society Vol. 70; no. 3
• Main Authors: Bielawski, K, Rhone, P, Bielawska, S, Rosc, D, Brkic, A, Zarychta, E, Ruszkowska-Ciastek, B
• Format: Journal Article
• Language: English
• Published: Poland 01-06-2019
• Subjects: Adult; Aged; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Female; Glucuronidase - metabolism; Humans; Immunohistochemistry - methods; Lymphatic Metastasis - pathology; Male; Middle Aged; Neovascularization, Pathologic - metabolism; Neovascularization, Pathologic - pathology; Receptor, ErbB-2 - metabolism; Receptors, Progesterone - metabolism; Survival Rate
• ISSN: 1899-1505
• DOI: 10.26402/jpp.2019.3.13

Heparanase concentration is low in normal epithelia cells but its overexpression is reported in many carcinomas, including sarcomas and haematological malignancies. The purpose of this study was to investigate the association with selected angiogenic parameters as well as in the number of circulating endothelial progenitors (EPCs) in respect to low, moderate and high concentrations of heparanase. Also, we estimated the diagnostic usefulness of the heparanase concentration for disease recurrence prediction in breast cancer cases. Eighty-six patients with IA-IIB stage invasive breast carcinoma who passed a comprehensive clinicopathologic evaluation were included in the study. The median tumour diameter was 1.5 cm. Twenty cases showed lymph node metastasis (N1). Follow-up was completed in all patients a median follow-up was 33.5 months with a 11.6% recurrence rate. An immunoassay of selected angiogenic parameters, heparanase, as well as an immunohistochemistry of oestrogen and progesterone receptors, human epidermal growth factor receptor 2 (HER2), Ki67 and E-cadherin was performed in all cases. Circulating EPCs were determined by flow cytometry. Higher levels of heparanase in oestrogen and progesterone receptor negative cancers than in positive ones were noted. A higher concentration of heparanase was observed in T2 cases than T1 subjects. Significant positive associations between circulating EPCs, soluble forms of VEGF receptors and increasing plasma levels of heparanase were obtained. Follow-up revealed a significantly higher incidence of disease relapse in breast cancer patients with high baseline concentrations of heparanase. Heparanase was the most accurate biomarker with an AUC
= 0.72. The cut-off value of 213.74 pg/mL was identified in order to discriminate between disease recurrence patients and those without disease relapse. We suggest, that a high concentration of heparanase next to tumour size and oestrogen and progesterone receptor expression may serve as an indicator of a more an aggressive character of tumour cells and a shorter survival rate.